Invitrogen, Lentigen to Provide Lentivirus Products and Services for Gene Over-Expression

Invitrogen Corporation and Lentigen Corporation have announced a partnership to develop and supply gene over-expression products and services. Invitrogen will exclusively commercialize the products and services from the partnership.

Lentiviral vectors are widely accepted in the research community as an effective tool for gene delivery into all mammalian cell types, including neural, blood, and stem cells.

Under the agreement, Invitrogen will provide access to its extensive human and mouse gene libraries for use by Lentigen for the development of ready-to-use lentiviral particles that deliver enhanced functionality and reliability.

Access to these lentiviral products and services will substantially reduce the time that many researchers currently spend to prepare and characterize lentivirus particles in their own laboratories.